RESUMEN
Ifetroban is a potent and selective thromboxane receptor antagonist. This study was conducted to characterize the pharmacokinetics, absolute bioavailability, and disposition of ifetroban after i.v. and oral administrations of [14C]ifetroban or [3H]ifetroban in rats (3 mg/kg), dogs (1 mg/kg), monkeys (1 mg/kg), and humans (50 mg). The drug was rapidly absorbed after oral administration, with peak plasma concentrations occurring between 5 and 20 min across species. Plasma terminal elimination half-life was approximately 8 h in rats, approximately 20 h in dogs, approximately 27 h in monkeys, and approximately 22 h in humans. Based on the steady-state volume of distribution, the drug was extensively distributed in tissues. Absolute bioavailability was 25, 35, 23, and 48% in rats, dogs, monkeys, and humans, respectively. Renal excretion was a minor route of elimination in all species, with the majority of the dose being excreted into the feces. After a single oral dose, urinary excretion accounted for 3% of the administered dose in rats and dogs, 14% in monkeys, and 27% in humans, with the remainder excreted in the feces. Extensive biliary excretion was observed in rats with the hydroxylated metabolite at the C-14 position being the major metabolite observed in rat bile. Ifetroban was extensively metabolized after oral administration. Approximately 40 to 50% of the radioactivity in rat and dog plasma was accounted for by parent drug whereas, in humans, approximately 60% of the plasma radioactivity was accounted for by ifetroban acylglucuronide.
Asunto(s)
Compuestos Bicíclicos Heterocíclicos con Puentes/farmacocinética , Oxazoles/farmacocinética , Receptores de Tromboxanos/antagonistas & inhibidores , Administración Oral , Adulto , Animales , Bilis/metabolismo , Líquidos Corporales/metabolismo , Compuestos Bicíclicos Heterocíclicos con Puentes/sangre , Compuestos Bicíclicos Heterocíclicos con Puentes/orina , Chlorocebus aethiops , Estudios Cruzados , Perros , Humanos , Masculino , Oxazoles/sangre , Oxazoles/orina , Inhibidores de Agregación Plaquetaria/sangre , Inhibidores de Agregación Plaquetaria/farmacocinética , Inhibidores de Agregación Plaquetaria/orina , Ratas , Ratas Sprague-Dawley , Especificidad de la Especie , Factores de Tiempo , Distribución TisularRESUMEN
The objective of this study was to assess the effect of food on the pharmacokinetics of nefazodone (NEF). A group of 24 healthy adult male volunteers received a single 200 mg dose of NEF under fasting conditions as well as 5 min after a high-fat breakfast. There was a 1 week washout between treatments. Serial blood samples were collected for 48 h after dosing and assayed by a validated HPLC method for NEF and the metabolites hydroxynefazodone (HO-NEF), m-chlorophenylpiperazine (mCPP), and triazoledione (dione). The mean (SD) peak concentration (Cmax) for NEF was not affected by food and was 416 (220) ng mL-1 and 446 (271) ng mL-1 after the fed and fasted treatments, respectively. The median time to reach Cmax (Tmax) was also unaffected by food and was 2 h for both treatments. However, the mean (SD) area under the curve (AUC) was significantly reduced by food from 1815 (1017) ng h mL-1 to 1409 (695) ng h mL-1. Although there was an 18% decrease in NEF AUC when administered with food, food had no effect on Cmax and Tmax values for NEF, HO-NEF, mCPP or dione or AUC values for HO-NEF, mCPP, or dione, indicating that NEF can be administered without regard to meals.
Asunto(s)
Antidepresivos de Segunda Generación/farmacocinética , Grasas de la Dieta/farmacología , Triazoles/farmacocinética , Adolescente , Adulto , Disponibilidad Biológica , Estudios Cruzados , Humanos , Masculino , Piperazinas , Valores de Referencia , ComprimidosRESUMEN
The effect of nefazodone on pharmacokinetic and pharmacodynamic parameters of digoxin were evaluated in an open, randomized, multiple-dose, three-way crossover study of 18 healthy male volunteers. The volunteers received nefazodone alone (200 mg twice daily), digoxin alone (0.2 mg daily), or nefazodone combined with digoxin during three 8-day treatment periods, with a single dose on the ninth day. There was a 10-day washout period between treatment periods. Coadministration of nefazodone with digoxin had no effect on the frequency and severity of adverse events compared with those observed with either drug alone. Steady-state area under the concentration-time curve (AUC) and peak (Cmax) and trough (Cmin) concentrations of digoxin were significantly higher (15%, 29%, and 27%, respectively) after coadministration of nefazodone/digoxin than after administration of digoxin. Despite these increases, no clinically significant changes in vital signs, heart rate, or PR, QRS, and QT intervals on the electrocardiogram occurred after coadministration from those measured after digoxin monotherapy. Coadministration did not affect the pharmacokinetics of nefazodone or its metabolites (hydroxynefazodone, m-chlorophenylpiperazine, triazole dione). Because digoxin has a narrow therapeutic index, monitoring of plasma digoxin levels and appropriate adjustment of dosage are recommended when nefazodone and digoxin are administered concurrently.
Asunto(s)
Antidepresivos de Segunda Generación/farmacología , Antidepresivos de Segunda Generación/farmacocinética , Cardiotónicos/farmacología , Cardiotónicos/farmacocinética , Digoxina/farmacología , Digoxina/farmacocinética , Triazoles/farmacología , Triazoles/farmacocinética , Adulto , Antidepresivos de Segunda Generación/efectos adversos , Cardiotónicos/efectos adversos , Estudios Cruzados , Digoxina/efectos adversos , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Interacciones Farmacológicas , Electrocardiografía/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Piperazinas , Triazoles/efectos adversosRESUMEN
The effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline was evaluated in a multiple-dose, randomized placebo-controlled, double-blind two-period crossover study in 13 patients who were undergoing theophylline therapy for chronic obstructive pulmonary disease. Two treatments were administered, each for 7 days: theophylline + 200 mg nefazodone twice daily (every 12h) and theophylline+matching nefazodone placebo capsule twice daily (every 12h). Mean peak and trough plasma concentrations of theophylline ranged from 13.1 to 14.5 micrograms ml-1 and 11.6 to 14.2 micrograms ml-1, respectively, at steady-state when theophylline was administered with or without concurrent dosing of nefazodone. Similarly, the mean area under the curve for theophylline ranged from 93.5 to 103 micrograms ml-1 h. When nefazodone and theophylline were co-administered, theophylline pharmacokinetic parameters did not significantly differ from those obtained when theophylline was administered with placebo. Forced expiratory volume in one second (FEV1) measurements taken when nefazodone or placebo were administered with theophylline did not differ from those obtained at baseline. The plasma concentration-time profiles for nefazodone and its metabolites were similar to those in other studies where nefazodone was administered alone. Since nefazodone did not affect the pharmacokinetics or the pharmacodynamics of theophylline, no change in theophylline dose should be needed as a consequence of nefazodone co-administration.
Asunto(s)
Antidepresivos/farmacología , Broncodilatadores/farmacocinética , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Teofilina/farmacocinética , Triazoles/farmacología , Antidepresivos/administración & dosificación , Broncodilatadores/administración & dosificación , Estudios Cruzados , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Enfermedades Pulmonares Obstructivas/metabolismo , Masculino , Piperazinas , Teofilina/administración & dosificación , Triazoles/administración & dosificaciónRESUMEN
This study was conducted to determine the potential for an interaction between nefazodone, a new antidepressant, and alprazolam after single- and multiple-dose administration in a randomized, double-blind, parallel-group, placebo-controlled study in 48 healthy male volunteers. A group of 12 subjects received either placebo twice daily, 1 mg of alprazolam twice daily, 200 mg of nefazodone twice daily, or the combination of 1 mg of alprazolam and 200 mg of nefazodone twice daily for 7 days. Serial blood samples were collected after dosing on day 1 and day 7 and before the morning dose on days 4, 5, and 6 for the determination of alprazolam and its metabolites alpha-hydroxyalprazolam (AOH) and 4-hydroxyalprazolam (4OH) and nefazodone and its metabolites hydroxynefazodone (HO-nefazodone), m-chlorophenylpiperazine (mCPP), and a triazole dione metabolite (dione) by validated high-performance liquid chromatography methods. Steady-state levels in plasma were reached by day 4 for alprazolam, 4OH, nefazodone, HO-nefazodone, mCPP, and dione. Noncompartmental pharmacokinetic analysis showed that at steady state, alprazolam Cmax and AUCtau values significantly increased approximately twofold and 4OH Cmax and AUCtau values significantly decreased by 40 and 26%, respectively, when nefazodone was coadministered with alprazolam. There was no effect of alprazolam on the single-dose or steady-state pharmacokinetics of nefazodone, HO-nefazodone, or dione after the coadministration of alprazolam and nefazodone. However, the mean steady-state mCPP Cmax and AUCtau significantly increased by approximately threefold and t1/2 values significantly increased by approximately twofold after the coadministration of alprazolam and nefazodone in comparison to those when nefazodone was given alone. Competitive inhibition between alprazolam and nefazodone metabolism at cytochrome P450 3A4 may be responsible for the pharmacokinetic interaction when alprazolam and nefazodone were coadministered. No adjustment of nefazodone dosage is required when nefazodone and alprazolam are coadministered. Because alprazolam concentrations in plasma are increased in the presence of nefazodone, a reduction in alprazolam dosage is recommended when the two agents are coadministered.
Asunto(s)
Alprazolam/efectos adversos , Ansiolíticos/efectos adversos , Antidepresivos/efectos adversos , Triazoles/efectos adversos , Adulto , Alprazolam/administración & dosificación , Alprazolam/farmacocinética , Ansiolíticos/administración & dosificación , Ansiolíticos/farmacocinética , Antidepresivos/administración & dosificación , Antidepresivos/farmacocinética , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Esquema de Medicación , Interacciones Farmacológicas , Quimioterapia Combinada , Humanos , Masculino , Piperazinas , Triazoles/administración & dosificación , Triazoles/farmacocinéticaRESUMEN
This study was conducted to determine the potential for an interaction between nefazodone (NEF), a new antidepressant, and lorazepam (LOR) after single- and multiple-dose administration in a randomized, double-blind, parallel-group, placebo-controlled study in healthy male volunteers. A total of 12 subjects per group received either placebo (PLA) twice daily, 2 mg of LOR twice daily, 200 mg of NEF twice daily, or the combination of 2 mg of LOR and 200 mg of NEF (LOR+NEF) twice daily for 7 days. Plasma samples were collected after dosing on day 1 and day 7 and before the morning dose on days 4, 5, and 6 for the determination of LOR, NEF, and NEF metabolites hydroxy (HO)-NEF, m-chlorophenylpiperazine (mCPP), and dione by validated high-performance liquid chromatography methods. Steady-state levels in plasma were reached by day 4 for LOR, NEF, HO-NEF, mCPP, and dione. Noncompartmental pharmacokinetic analysis showed that there was no effect of LOR on the single dose or steady-state pharmacokinetics of NEF, HO-NEF, or dione after coadministration. The steady-state mCPP Cmax values decreased 36% for the LOR+NEF group in comparison to that when NEF was given alone. There was no effect of NEF on the pharmacokinetics of LOR after coadministration. The absence of an interaction appears to be attributable to LOR's metabolic clearance being dependant on conjugation rather than hydroxylation. Overall, no change in LOR or NEF dosage is necessary when the two drugs are coadministered.
Asunto(s)
Ansiolíticos/efectos adversos , Antidepresivos/efectos adversos , Lorazepam/efectos adversos , Triazoles/efectos adversos , Adulto , Ansiolíticos/administración & dosificación , Ansiolíticos/farmacocinética , Antidepresivos/administración & dosificación , Antidepresivos/farmacocinética , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Interacciones Farmacológicas , Quimioterapia Combinada , Humanos , Lorazepam/administración & dosificación , Lorazepam/farmacocinética , Masculino , Piperazinas , Triazoles/administración & dosificación , Triazoles/farmacocinéticaRESUMEN
Nefazodone, an antidepressant with serotonin and norepinephrine receptor modulating activity, is highly protein bound and eliminated by oxidative metabolism. This study evaluated the potential for clinically significant drug interactions with warfarin and nefazodone coadministration. Eighteen subjects received warfarin daily for 14 days, achieving steady-state warfarin concentrations and a stable prothrombin ratio. Nefazodone 200 mg every 12 hours (n = 12) or placebo every 12 hours (n = 6) was then added to the daily warfarin dose for the next 7 days in a double-blind, randomized design. No serious or unexpected adverse events or events suggestive of abnormal bleeding occurred during coadministration. The addition of nefazodone had no effect on the unbound fraction of total warfarin in plasma or on the steady-state pharmacokinetics of R-warfarin based on within-subject or comparison to placebo-treated subjects. The steady-state AUCTAU over the dosing interval and Cmax of S-warfarin decreased by 12%; however, this change is clinically insignificant because the prothrombin ratio and bleeding time remained unchanged. The steady-state minimum concentrations for nefazodone and metabolites, achieved on coadministration day 3, were typical of healthy men treated with this nefazodone dosage. In conclusion, warfarin and nefazodone coadministration was safe and well-tolerated with no clinically significant interactions.
Asunto(s)
Anticoagulantes/farmacología , Antidepresivos/farmacología , Triazoles/farmacología , Warfarina/farmacología , Adulto , Anticoagulantes/administración & dosificación , Anticoagulantes/farmacocinética , Antidepresivos/administración & dosificación , Antidepresivos/farmacocinética , Método Doble Ciego , Esquema de Medicación , Interacciones Farmacológicas , Humanos , Masculino , Piperazinas , Comprimidos , Triazoles/administración & dosificación , Triazoles/farmacocinética , Warfarina/administración & dosificación , Warfarina/farmacocinéticaRESUMEN
A method for the high-performance liquid chromatographic (HPLC) determination of serum concentrations of d,l-4-amino-N-(alpha-methylbenzyl)-benzamide and its N-acetylated metabolite is described. The compounds are isolated from a 50-microL sample of serum using solid phase extraction. The compounds and internal standard are eluted from the extraction column with acetonitrile. Quantitation is performed via UV detection at 275 nm following isocratic reversed-phase (C18) separation using a ternary solvent system. The assay procedure is useful for the determination of concentrations of parent compound from 0.63 to 87.9 micrograms/mL from 50 microL of serum.
Asunto(s)
Anticonvulsivantes/sangre , Benzamidas/sangre , Acetilación , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/farmacocinética , Fenómenos Químicos , Química , Cromatografía Líquida de Alta Presión , Humanos , Infusiones Intravenosas , Espectrofotometría UltravioletaRESUMEN
A series of 4- aminobenzamides of some simple primary and secondary amines were prepared and evaluated for anticonvulsant effects. The compounds were tested in mice against seizures induced by electroshock and pentylenetetrazole ( metrazole ) and in the rotorod assay for neurologic deficit. For those N-alkyl amides tested, 4-amino-N- amylbenzamide (6) was the most potent against maximal electroshock seizures (MES): ED50 = 42.98 mg/kg; however, the N- cyclohexylbenzamide (8) showed the greatest protective index (PI = TD50/ED50), 2.8. The introduction of a second aromatic ring produced more potent compounds, with d,l-4-amino-N-(alpha-methylbenzyl)-benzamide (12) showing the highest level of activity. This compound has an anti-MES ED50 of 18.02 mg/kg in mice when administered intraperitoneally (ip) and a TD50 of 170.78 mg/kg (PI = 9.5) in the same species. These data compare quite favorably with those for phenobarbital and phenytoin in the same assays.